- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06485908
Axitinib og oral metronomisk etoposid til pædiatriske børn og AYA refraktær/tilbagevendende medulloblastom og ependymom (MEPENDAX)
MEPENDAX: Fase I/II undersøgelse af Axitinib (Inlyta®) og oralt metronomisk etoposid til pædiatriske børn og AYA refraktær/tilbagevendende medulloblastom og ependymom
It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors. It is a two-stage trial:
First stage: To determine the Maximum Tolerated Dose (MTD) of the combination of axitinib and oral metronomic etoposide for patient with medulloblastoma or ependymoma Second stage: Extension cohort evaluating the preliminary efficacy at the recommended dose for the phase II (RDP2) of the combination. The 2nd stage will start after a meeting of independent data monitoring committee (IDMC). Two cohorts of 9 patients with ependymoma and medulloblastoma Patients treated at first stage won't be included in the second stage.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Nicolas ANDRE
- Telefonnummer: 0491386792
- E-mail: nicolas.andre@ap-hm.fr
Undersøgelse Kontakt Backup
- Navn: Franceline CARTIER
- E-mail: franceline.cartier@ap-hm.fr ; promotion.interne@ap-hm.fr
Studiesteder
-
-
-
Angers, Frankrig
- Rekruttering
- Centre Hospitalier Universitaire D'Angers
-
Kontakt:
- BRISSET
- Telefonnummer: 0241356524
- E-mail: claire.brisset@chu-angers.fr
-
Bordeaux, Frankrig
- Rekruttering
- Centre Hospitalier Universitaire De Bordeaux
-
Kontakt:
- ICHER
- Telefonnummer: 0557820448
- E-mail: celine.icher@chu-bordeaux.fr
-
Lyon, Frankrig
- Rekruttering
- IHOPe Institut d'Hématologie et d'Oncologie Pédiatrique
-
Kontakt:
- LEBLOND
- Telefonnummer: 0469166550
- E-mail: pierre.leblond@ihope.fr
-
Marseille, Frankrig
- Rekruttering
- Assistance Publique - Hôpitaux de Marseille
-
Kontakt:
- Nicolas Andre
- Telefonnummer: +330491386821
- E-mail: nicolas.andre@ap-hm.fr
-
Nancy, Frankrig
- Rekruttering
- CHRU De Nancy
-
Kontakt:
- Marie-Sophie MERLIN
- Telefonnummer: +33 0383154734
- E-mail: m.merlin@chru-nancy.fr
-
Paris, Frankrig
- Rekruttering
- Institut Curie
-
Kontakt:
- LERUSTE
- Telefonnummer: 0144324015
- E-mail: amaury.lereuste@curie.fr
-
Strasbourg, Frankrig
- Rekruttering
- Les Hopitaux Universitaires De Strasbourg
-
Kontakt:
- Natacha ENTZ-WERLE
- Telefonnummer: +33 0388128097
- E-mail: natacha.entz-werle@chru-strasbourg.fr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically proven diagnosis of ependymoma or medulloblastoma
- Methyloma classification performed or available material for methyloma analysis
- Confirmed progressive or refractory disease despite standard therapy, or for which no effective standard therapy exists
- Male and female subjects with > 4 to ≤ 25 years of age at inclusion
- Weight > 20 kg
- Evaluable target lesion(s) according to RAPNO
- Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Life expectancy ≥ 3 months
- No known allergy to any of the compounds in the experimental treatment
- Able to take oral treatments
- Adequate organ function:
Hematologic criteria
- Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 (unsupported)
- Platelet count ≥ 100,000/mm3 (unsupported)
- Hemoglobin ≥ 8.0 g/dL (transfusion is allowed) Cardiac function
- Shortening fraction (SF) >29% and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).
Renal and hepatic function
-
Serum creatinine < 1.5 x upper limit of normal (ULN) for age
-
Total bilirubin < 1.5 x ULN
-
Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST)/ < 2.5 x ULN
- Able to comply with scheduled follow-up and with management of toxicity.
- Females of child bearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
- Sexually active patients must agree to use adequate and appropriate contraception (in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) recommendations) while on study drug and for 6 months after stopping the study drug.
- Patient able to comfortably swallow capsules.
- Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
- Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.
Non-inclusion Criteria
- Chemotherapy within 21 days of day 1 from the start of study treatment. This period can be shortened in the case of treatment with vincristine (2 weeks) and extended to 6 weeks in the case of treatment with nitrosureas. The period is set to 5 half-lives in the case of targeted therapies or metronomic chemotherapy. The period is set to 2 weeks after bevacizumab administration. Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI or scan.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
- Presence of any NCI-CTCAE v5 grade ≥ 2 treatment-related extra-hematological toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.
- Known congenital immunodeficiency.
- Radiotherapy within the 2 months preceding D1 of the start of study treatment. Palliative RT on a non-target lesion is allowed up to 1 weeks before beginning of treatment.
- Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
- Bleeding disorder.
- Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
- Known hypersensitivity to any study drug or component of the formulation.
- Absence of effective contraception in patients of childbearing age (see appendix 3)
- Pregnant or nursing (lactating) females.
- Patients with galactose intolerance, lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary diseases).
- Severe infections requiring parenteral antibiotic therapy.
- Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Patients receiving axitinib in combination with etoposide
|
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Dose-limiting toxicity (DLT)
Tidsramme: During the first 28 days (cycle 1)
|
During first stage |
During the first 28 days (cycle 1)
|
|
Progression-free survival (PFS)
Tidsramme: 3 years (from start of treatment to last follow-up visit)
|
During second stage, progression-free survival (PFS) computed as the time interval from the beginning of treatment to the date of centrally-assessed with RAPNO criteria. A central review of all imaging is planned at the end of phase 1 and at the end of phase expansion to evaluate tumor response and progressions. PFS-duration of patients alive free of progression at last follow-up will be censored at the date of last visit. |
3 years (from start of treatment to last follow-up visit)
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Nicolas ANDRE, Assistance Publique - Hôpitaux de Marseille
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Gliom
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neuroektodermale tumorer, primitive
- Ependymom
- Medulloblastom
- Organiske kemikalier
- Kulbrinter
- Kulbrinter, cyklisk
- Kulhydrater
- Podophyllotoxin
- Tetrahydronaphthalenes
- Naphthalenes
- Polycykliske aromatiske kulbrinter
- Kulbrinter, aromatisk
- Polycykliske forbindelser
- Glukosider
- Glycosider
- Etoposid
Andre undersøgelses-id-numre
- RCAPHM23_0164
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .